Metagenomi Therapeutics, Inc.

MGX

Metagenomi Therapeutics, Inc.

MGX

Insider Sentiment (TTM):

Last Purchase:2024-02-13Last Sale:2026-06-05Shares Purchased (TTM):0Shares Sold (TTM):24,134

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:6,451,452Shares Outstanding:37,581,094Institutional Ownership Pct.:17.17%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	39	25	42	33	27	29	27	25	61	103
Available For Sale Securities Debt Securities Curr…	82	115	119	151	178	197	221	249	239	225
Accounts Receivable Net Current	0	0	0	1	1	1	1	1	2	2
Prepaid Expense And Other Assets Current	4	4	4	5	6	6	8	7	6	6
Assets Current	124	145	166	190	212	233	258	282	308	336
Property Plant And Equipment Net	10	11	12	14	15	17	18	20	21	21
Long Term Investments	2	2	2	2	2	3	3	11	11	11
Operating Lease Right Of Use Asset	32	34	35	36	37	39	40	40	41	42
Other Assets Noncurrent	1	1	1	1	1	1	0	0	0	0
Restricted Cash Noncurrent	4	4	5	5	5	5	5	5	5	5
Assets	174	197	221	248	272	298	325	358	386	415
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	2	1	1	3	3	1	3	3	7
Accrued Liabilities And Other Liabilities	8	5	7	10	6	6	8	9	11	7
Accrued Income Taxes Current	-	-	-	-	-	-	0	0	0	3
Operating Lease Liability Current	6	6	6	6	6	6	6	5	5	4
Contract With Customer Liability Current	11	9	9	13	19	26	23	29	33	48
Liabilities Current	28	22	23	30	33	40	37	46	53	71
Operating Lease Liability Noncurrent	31	33	35	36	37	39	40	41	43	44
Contract With Customer Liability Noncurrent	0	2	3	2	4	4	10	12	17	20
Other Liabilities Noncurrent	2	2	2	2	2	2	2	3	4	5
Liabilities	61	59	63	69	76	85	90	103	116	140
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0
Commitments And Contingencies	-	-	-	-	-	-	0	-	-	-
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	474	472	469	466	463	460	457	454	451	446
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	1	1	2	-0	-0
Retained Earnings Accumulated Deficit	-361	-334	-311	-288	-268	-248	-223	-200	-181	-170
Stockholders Equity	113	138	159	178	196	213	235	256	269	276
Liabilities And Stockholders Equity	174	197	221	248	272	298	325	358	386	415
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Authorized	-	-	-	-	-	-	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	-	-	-	0	0	0	0
Temporary Equity Shares Issued	-	-	-	-	-	-	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	38	38	38	38	38	37	37	37	37	37
Shares Outstanding	38	38	38	38	38	37	37	37	37	37

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.19%	-6.67%	-11.85%	-	-	-	-	-	-	-	-	-
2025	8.12%	4.37%	40.62%	1.60%	40.96%	35.11%	-4.30%	-10.22%	-17.20%	-18.01%	-6.83%	-16.15%
2024	-7.03%	-36.39%	-44.50%	-12.26%	-34.84%	-31.94%	-12.32%	71.56%	27.49%	-21.28%	-19.68%	-7.98%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Liquidity Ratios
Current Ratio	4.50	6.43	7.22	6.42	6.36	5.85	6.91	6.18	5.82	4.75
Quick Ratio	4.37	6.23	7.02	6.26	6.19	5.69	6.69	6.02	5.71	4.66
Working Capital	96.84M	122.06M	142.61M	160.24M	178.42M	193.30M	220.65M	236.60M	254.77M	264.94M
Leverage & Debt
Debt to Equity	0.54	0.43	0.39	0.39	0.39	0.40	0.38	0.40	0.43	0.51
Debt Ratio	0.35	0.30	0.28	0.28	0.28	0.29	0.28	0.29	0.30	0.34
Efficiency & Turnover
Asset Turnover TTM	0.06	0.09	0.09	0.10	0.10	0.13	0.16	-	-	-
Days Sales Outstanding TTM	-	-	11.31	9.14	13.62	12.47	8.77	-	-	-
Receivables Turnover TTM	-	-	32.28	39.91	26.79	29.26	41.60	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.48	-2.29	-2.36	-2.38	-2.34	-2.11	-2.36	-	-	-
Free Cash Flow Per Share TTM	-2.33	-2.34	-2.41	-1.86	-2.05	-2.82	-3.40	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Operating Profit Margin TTM	-727.79%	-415.48%	-380.85%	-298.48%	-271.89%	-193.73%	-170.00%	-	-	-
Net Profit Margin TTM	-676.38%	-384.61%	-348.54%	-287.06%	-257.99%	-172.21%	-149.26%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-59.08%	-50.66%	-51.79%	-	-	-	-	-	-	-
Net Income Growth (1Y)	7.28%	10.18%	12.57%	-	-	-	-	-	-	-
EPS Growth (1Y)	5.85%	8.54%	-0.19%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-0.48	-0.59	-0.69	-1.00	-0.63	-0.65	-1.53	-	-	-
P/B TTM	0.40	0.37	0.38	0.50	0.28	0.24	0.51	0.31	0.55	0.81
P/S TTM	3.24	2.26	2.39	2.86	1.63	1.11	2.28	-	-	-
Market Cap	44.81M	50.36M	60.35M	88.52M	54.99M	50.35M	119.23M	79.78M	149.43M	223.00M
Enterprise Value	1.39M	20.66M	13.43M	55.75M	22.89M	21.15M	86.60M	54.67M	88.25M	120.45M
Calculated Values
Free Cash Flow TTM	-87.73M	-87.86M	-89.79M	-69.64M	-76.15M	-104.55M	-112.19M	-	-	-
Net Debt	-43.42M	-29.70M	-46.92M	-32.77M	-32.10M	-29.20M	-32.63M	-25.12M	-61.18M	-102.56M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-05Sale

Owner: Wein, Matthew

Title: See Remarks

Shares: 558

Price/Share: $1.30

Value: $725.40

Shares Owned: 126,491

Relationship: Officer

Ownership: Direct

2026-06-05Sale

Owner: Wapnick, Pamela

Title: Chief Financial Officer

Shares: 2,884

Price/Share: $1.30

Value: $3,749.20

Shares Owned: 208,491

Relationship: Officer

Ownership: Direct

2026-06-05Sale

Owner: Irish, Jian

Title: See Remarks

Shares: 3,737

Price/Share: $1.30

Value: $4,858.10

Shares Owned: 377,533

Relationship: Director,Officer

Ownership: Direct

2026-03-05Sale

Owner: Wein, Matthew

Title: See Remarks

Shares: 482

Price/Share: $1.60

Value: $771.20

Shares Owned: 114,549

Relationship: Officer

Ownership: Direct

2026-03-05Sale

Owner: Irish, Jian

Title: Chief Executive Officer

Shares: 1,607

Price/Share: $1.60

Value: $2,571.20

Shares Owned: 333,770

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-05	Wein, Matthew	Officer	See Remarks	Direct	Sale	558	1.30	$725.40	126,491	4
2026-06-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	2,884	1.30	$3,749.20	208,491	4
2026-06-05	Irish, Jian	Director,Officer	See Remarks	Direct	Sale	3,737	1.30	$4,858.10	377,533	4
2026-03-05	Wein, Matthew	Officer	See Remarks	Direct	Sale	482	1.60	$771.20	114,549	4
2026-03-05	Irish, Jian	Director,Officer	Chief Executive Officer	Direct	Sale	1,607	1.60	$2,571.20	333,770	4
2026-03-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,581	1.60	$2,529.60	187,375	4
2025-12-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,576	1.77	$2,789.52	188,956	4
2025-12-05	Thomas, Brian C.	Director	-	Direct	Sale	3,830	1.77	$6,779.10	2,510,960	4
2025-12-05	Wein, Matthew	Officer	See Remarks	Direct	Sale	199	1.77	$352.23	115,031	4
2025-12-05	Irish, Jian	Director,Officer	Chief Executive Officer	Direct	Sale	1,602	1.77	$2,835.54	563,839	4
2025-09-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,576	1.81	$2,852.56	70,532	4
2025-09-05	Irish, Jian	Director,Officer	Chief Executive Officer	Direct	Sale	1,602	1.81	$2,899.62	316,941	4
2025-09-05	Wein, Matthew	Officer	See Remarks	Direct	Sale	199	1.81	$360.19	19,230	4
2025-09-05	Thomas, Brian C.	Director	-	Direct	Sale	2,701	1.81	$4,888.81	2,514,790	4
2025-06-06	Noonberg, Sarah B.	Officer	Chief Medical Officer	Direct	Sale	5,239	1.75	$9,168.25	109,135	4
2025-06-06	Thomas, Brian C.	Director,Officer	Chief Executive Officer	Direct	Sale	10,785	1.75	$18,873.75	2,517,491	4
2025-06-06	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,576	1.75	$2,758.00	72,108	4
2025-06-06	Wein, Matthew	Officer	See Remarks	Direct	Sale	199	1.75	$348.25	16,693	4
2025-06-06	Irish, Jian	Director,Officer	See Remarks	Direct	Sale	6,390	1.75	$11,182.50	315,543	4
2025-03-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,808	1.87	$3,380.96	59,684	4
2025-03-05	Wein, Matthew	Officer	See Remarks	Direct	Sale	930	1.87	$1,739.10	9,467	4
2024-12-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	1,559	1.86	$2,899.74	61,492	4
2024-09-05	Wapnick, Pamela	Officer	Chief Financial Officer	Direct	Sale	6,265	2.88	$18,043.20	63,051	4
2024-02-13	Novo, Holdings A/S	TenPercentOwner	-	Direct	Purchase	800,000	15.00	$12,000,000.00	1,739,175	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

17.17%

Inst. Shares: 6,451,452

Shares Outstanding: 37,581,094

2025-12-31

17.95%

Inst. Shares: 6,688,014

Shares Outstanding: 37,251,050

2025-09-30

16.03%

Inst. Shares: 5,986,092

Shares Outstanding: 37,349,449

2025-06-30

17.96%

Inst. Shares: 6,674,067

Shares Outstanding: 37,156,979

2025-03-31

25.35%

Inst. Shares: 9,383,167

Shares Outstanding: 37,019,027

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	6,451,452	37,581,094	17.17%
2025-12-31	6,688,014	37,251,050	17.95%
2025-09-30	5,986,092	37,349,449	16.03%
2025-06-30	6,674,067	37,156,979	17.96%
2025-03-31	9,383,167	37,019,027	25.35%
2024-12-31	10,529,186	33,027,889	31.88%
2024-09-30	10,399,518	36,766,309	28.29%
2024-06-30	11,379,916	36,625,291	31.07%
2024-03-31	12,377,246	21,137,868	58.55%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Metagenomi Therapeutics, Inc. (MGX) — SEC Financial Statements & Analysis

Metagenomi Therapeutics, Inc. (MGX) is a biological products, (no diagnostic substances) company. Metagenomi Therapeutics, Inc. trades on Nasdaq as: MGX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Metagenomi Therapeutics, Inc. reported a -59.08% year-over-year revenue growth, a Debt-to-Equity ratio of 0.54x, a Price-to-Sales (P/S) ratio of 3.24x (TTM), a Price-to-Book (P/B) ratio of 0.40x (TTM), at a market cap of $44.81M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -59.08%
Debt To Equity: 0.54x
P/S TTM: 3.24x
P/B TTM: 0.40x
Market Cap: $44.81M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Metagenomi Therapeutics, Inc. in?

Metagenomi Therapeutics, Inc. (MGX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is MGX's market cap?

Metagenomi Therapeutics, Inc. (MGX) has a market capitalization of $44.81M as of 2026-06-30.

What exchange does MGX trade on?

Metagenomi Therapeutics, Inc. (MGX) trades on the Nasdaq.